

Image 02-27-04

Docket No: AHP92038-2-C  
Patent

\$FW 1648/Box sec



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re of Application of: Alan R. Davis et al.  
Application No.: 09/457,421 Group Art No.: 1648  
Filed: December 7, 1999 Examiner: Le, Emily M.  
For: RECOMBINANT ADENOVIRUS VACCINES  
Confirmation No.: 7663  
Customer Number: 25291

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed please find the following documents for the above-identified application:

1. Information Disclosure Statement
2. Form PTO-1449
3. Sequence Listing
4. Sequence Listing Disk
5. Rule 821 (f) Statement

The Commissioner is hereby authorized to charge any additional fees required by this paper, including the enclosed documents, and during the entire pendency of this application and to credit any excess amounts paid to Deposit Account No. 01-1425. A copy of this letter is enclosed for use by the Deposit Account Branch.

Respectfully submitted,

Bill T. Brazil  
Agent for Applicants  
Reg. No. 50,733

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (732) 274-4843

**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV295518663US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

February 25, 2004  
Date

Carole K Kamrad  
Carole K. Kamrad



Docket No: AHP92038-2-C  
Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re of Application of: Alan R. Davis et al.  
Application No.: 09/457,421      Group Art No.: 1648  
Filed: December 7, 1999      Examiner: Le, Emily M.  
For: RECOMBINANT ADENOVIRUS VACCINES  
Confirmation No.: 7663  
Customer Number: 25291

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

**CERTIFICATE OF MAILING 37 CFR §1.10**

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EV295518663US addressed to the Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

February 25, 2004  
Date

Carole K. Kamrad  
Carole K. Kamrad

03/01/2004 BSAYASI1 00000012 011425 09457421  
01 FC:1806 180.00 DA

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☐ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☒ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☐ Certification under 37 CFR 1.97(e) and 1.704(d)  
The undersigned attorney certifies

- a. ☐ that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☐ Newly Cited Information

A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed, and if this patent application was filed or entered the national stage after June 30, 2003, no copy of a U.S. patent or U.S. patent application publication is enclosed.

☒ Previously Cited Information

No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.

Prior application is Application Number 08/276,289, filed on July 20, 1994, now abandoned, which is a continuation-in-part of application number 08/105,232, filed August 11, 1993, now abandoned, which is a continuation-in-part of application number 07/926,491, filed August 07, 1992, now abandoned.


- ☐ Concise Explanation  
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☐ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☒ Fees
- ☒ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:  
Charge Deposit Account No. 01-1425 in the amount of \$180.00  
A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:  
Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.

  
\_\_\_\_\_  
Bill T. Brazil  
Agent for Applicants  
Reg. No. 50,733

Wyeth  
Patent Law Department  
Five Giralda Farms  
Madison, NJ 07940  
Tel. No. (732) 274-4843

Substitute for form 1449/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

## Complete if Known

Application Number	09/457,421
Filing Date	December 7, 1999
First Named Inventor	Alan R. Davis
Group Art Unit	1648
Examiner Name	Le, Emily M.
Attorney Docket Number	AHP92038-2-C

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	Number (If known)	Kind Code (If Known)			
		4920209		Davis et al.	04-24-90	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.	EPO	80806	A1	Research Corporation	06-08-1983		<input type="checkbox"/>
	3.	PCT	WO83/02393	A1	Animal Vaccine Research Corporation	07-21-1983		
	4.	UK	GB2166349	A	American Home Products Corporation	05-08-1986		
	5.	PCT	WO91/13909	A1	Proteus Molecular Design LTD.	09-19-1991		

## OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	6.	R. J. NATUK, Vaccine Res., 1992, 1:275	<input type="checkbox"/>
	7.	P. K. CHANDA, Virology, 1990, 175:535	
	8.	S. K. VERNON <i>et al.</i> , Journal of General Virology, 1991, 72:1243-1251	
	9.	M. B. FEINBERG, Cell, 1986, 46:807	
	10.	J. SODROSKI, Nature, 1986, 321:412	
	11.	M. CONNORS, Vaccine, 1992, 10:475	
	12.	M. GORZIGLIA, J. Virol., 1992, 66:4407	
	13.	R. N. HJORTH, Arch. Virol., 1988, 100:279	
	14.	G. S. MARSHALL, J. Infect. Dis., 1990, 162:1177	
	15.	P. P. HUNG, Nat. Immun. Cell Growth Regul., 1988, 7:135	
	16.	J. E. MORIN, Proc. Natl. Acad. Sci. USA, 1987, 84:4626-4630	
	17.	P. K. CHANDA <i>et al.</i> , Intern. Rev. Immunol., 1990, 7:67-77	
	18.	R. CROWL, Cell, 1985, 41:979	
	19.	S. D. PUTNEY, Science, 1986, 232:1392	
	20.	D. D. HO, J. Virol., 1987, 61:2024	
	21.	P. L. NARA, Proc. Natl. Acad. Sci. USA, 1987, 34:3797	
	22.	T. W. CHANG, Bio/Technology, 1985, 3:095	
	23.	G. J. DAWSON, J. Infect. Dis., 1988, 157:149	
	24.	S. CHAKRABARTI, Nature, 1986, 320:535	
	25.	R. L. DEWAR, J. Virol., 1989, 63:129	
	26.	D. REKOSH, Proc. Natl. Acad. Sci. USA, 1988, 85:334	
	27.	M. E. WHEALY, J. Virol., 1988, 62:4185	
	28.	P. J. BARR, Vaccine, 1987, 5:90	
	29.	S. HU, Nature, 1978, 328:721	
	30.	J. R. RUSCHE, Proc. Natl. Acad. Sci. USA, 1987, 84:6294	
	31.	S. HU, J. Virol., 1987, 61:3617	
	32.	P. W. BERMAN, Proc. Natl. Acad. Sci. USA, 1988, 85:5200	
	33.	J. M. ZARLING, J. Immunol., 1987, 139:988	
	34.	J. GOUDSMIT, Proc. Natl. Acad. Sci. USA, 1988, 85:4478	
	35.	D. ZAGURY <i>et al.</i> , Nature, 1988, 332(21):728-731	
	36.	B. H. HAHN, Proc. Natl. Acad. Sci. USA, 1985, 82:4813	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Substitute for form 1449/PTO			<b>Complete if Known</b>		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)			Application Number	09/457,421	
			Filing Date	December 7, 1999	
			First Named Inventor	Alan R. Davis	
			Group Art Unit	1648	
			Examiner Name	Le, Emily M.	
Sheet	2	of	2	Attorney Docket Number	AHP92038-2-C

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	37.	R. C. DESROSIERS, Proc. Natl. Acad. Sci. USA, 1989, 86:6353		T
	38.	F. BARRE-SINOUSI, Science, 1983, 220:868		
	39.	R. C. GALLO, Science, 1984, 224:500		
	40.	M. POPOVIC, Science, 1984, 224:497		
	41.	M. SARNGADHARAN, Science, 1984, 224:506		
	42.	R. J. NATUK <i>et al.</i> , Journal of Acquired Immune Deficiency, 1993, 6:681		
	43.	R. J. NATUK <i>et al.</i> , AIDS Research and Human Retroviruses, 1993, 9(5):395-404		
	44.	R. J. NATUK <i>et al.</i> , Vaccine Research, 1992, 1:275		
	45.	R. J. NATUK <i>et al.</i> , Recombinant Vectors in Vaccine Dev., Brown ed., 1994, 82:71		
	46.	R. J. NATUK <i>et al.</i> , Huitieme Colloque Des Cent Gardes, 1993, pg. 115-120		
	47.	M. ROBERT-GURROFF <i>et al.</i> , J. Virology, 1998, 72:10,275-10,280		
	48.	FAHEY <i>et al.</i> , Clin. Exp. Immunol., 1992, 88:1-5		
	49.	FOX, BioTechnology, 1994, 12:128		
	50.	HAYNES <i>et al.</i> , Ann. Med., 1996, 28:39-41		
	51.	DOMBROWSKI <i>et al.</i> , Infection, 2000, 28:323-325		
	52.	J. COHEN, Science, 2000, 292:25-26		
	53.	R. J. NATUK <i>et al.</i> , Dev. Biol. Stand., 1995, 84:153-156		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.